AIM ImmunoTech Inc (NYSE:AIM) has announced that the Netherlands Patent Office has granted the company a utility patent covering rugged dsRNA, a double-stranded RNA product related to its lead candidate Ampligen (rintatolimod), which claims cover, among other aspects, compositions, and compositions for use in the prevention or treatment of COVID-19.
The new patent broadens AIM’s existing portfolio for COVID-19 treatments to include rugged dsRNA, the company said.
Ampligen is an immuno-modulator with broad-spectrum activity being developed by AIM for globally important cancers, viral diseases, and disorders of the immune system.
READ: AIM ImmunoTech promotes Christopher McAleer to the role of scientific officer
The company noted that data from in vitro, pre-clinical and clinical experiments strongly suggest that Ampligen has a broad-spectrum early-onset antiviral effect by stimulating a powerful innate immune response.
It added that AIM has conducted experiments in SARS-CoV-2 showing Ampligen has a powerful impact on viral replication.
AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie